Successful management of bleeding with recombinant factor VIIa (NovoSeven®) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins

We present the case of an 18‐year‐old female with Burkitt lymphoma involving the intra‐abdominal and inguinal lymph nodes. The tumor had invaded the left femoral and common iliac veins causing secondary thrombosis and vessel occlusion. Chemotherapy and anticoagulant treatment resulted in mild thromb...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Blood & Cancer 2007-09, Vol.49 (3), p.332-335
Main Authors: Čulić, Srđana, Kuljis, Dubravka, Armanda, Višnja, Jankovic, Stipan
Format: Article
Language:English
Subjects:
Adolescent
Anticoagulants - adverse effects
Antineoplastic Agents - adverse effects
bleeding
Burkitt lymphoma
Burkitt Lymphoma - complications
Burkitt Lymphoma - drug therapy
Factor VIIa - therapeutic use
Female
Femoral Vein
Heparin, Low-Molecular-Weight - adverse effects
Humans
Iliac Vein
Postoperative Hemorrhage - drug therapy
Postoperative Hemorrhage - etiology
recombinant factor VIIa
Recombinant Proteins - therapeutic use
Thrombocytopenia - chemically induced
Thrombocytopenia - complications
thrombosis
Venous Thrombosis - drug therapy
Venous Thrombosis - etiology
Venous Thrombosis - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present the case of an 18‐year‐old female with Burkitt lymphoma involving the intra‐abdominal and inguinal lymph nodes. The tumor had invaded the left femoral and common iliac veins causing secondary thrombosis and vessel occlusion. Chemotherapy and anticoagulant treatment resulted in mild thrombocytopenia and a prolonged prothrombin time, respectively, which exacerbated postoperative bleeding following surgical removal of a deep inguinal necrosis. After 6 days, bleeding combined with epistaxis was considered to be life threatening and anticoagulant reversal with recombinant factor VIIa was successfully performed. The patient has since achieved complete remission and subsequent antithrombotic therapy has resolved the vascular occlusion. Pediatr Blood Cancer 2007;49:332–335. © 2006 Wiley‐Liss, Inc.
ISSN:1545-5009
1545-5017
1096-911X
DOI:10.1002/pbc.20808